Novartis leads list of 2012's 20 biggest spenders for R&D

03/12/2013 | Genetic Engineering & Biotechnology News

Novartis, Roche Holding and Merck topped this ranking of biopharmaceutical companies based on spending for research and development last year. Pfizer and Johnson and Johnson came in fourth and fifth, respectively. Also making the top 10 were Sanofi, GlaxoSmithKline, Eli Lilly and Co., AstraZeneca and Abbott Laboratories.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care